Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

[1]  L. Montuenga,et al.  The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042 , 2019, Journal of clinical medicine.

[2]  J. Murakami,et al.  Depletion of Lipid Efflux Pump ABCG1 Triggers the Intracellular Accumulation of Extracellular Vesicles and Reduces Aggregation and Tumorigenesis of Metastatic Cancer Cells , 2018, Front. Oncol..

[3]  A. Villalobo,et al.  Ca2+ signaling and Src-kinases-controlled cellular functions. , 2018, Archives of biochemistry and biophysics.

[4]  Yong Teng,et al.  Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib , 2018, Journal of Hematology & Oncology.

[5]  Hua Guo,et al.  Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC. , 2018, Cancer research.

[6]  Kun Li,et al.  TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  Ye Zhang,et al.  Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance , 2017, Cancer science.

[8]  Xin Tong,et al.  ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma , 2016, Tumor Biology.

[9]  R. Hammond,et al.  Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients , 2016, BMC Cancer.

[10]  P. Schirmacher,et al.  SRC inhibition represents a potential therapeutic strategy in liposarcoma , 2015, International journal of cancer.

[11]  Yiqi Wu,et al.  Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients. , 2015, Oncology letters.

[12]  T. Murakami,et al.  Surgical and Locoregional Therapy of HCC: TACE , 2015, Liver Cancer.

[13]  Liang Zhao,et al.  The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M , 2015, BMC Cancer.

[14]  M. Mclaughlin,et al.  CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases , 2015, Oncogene.

[15]  S. Iwakawa,et al.  Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. , 2015, Biological & pharmaceutical bulletin.

[16]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[17]  R. Sakai,et al.  Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors , 2014, Cancer science.

[18]  Z. Ren,et al.  Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma Is Associated with Increased Autocrine of IGF1 , 2014, PloS one.

[19]  S. Thongprasert,et al.  Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Moens,et al.  P2Y12 receptor signalling towards PKB proceeds through IGF-I receptor cross-talk and requires activation of Src, Pyk2 and Rap1. , 2006, Cellular signalling.

[21]  D. Coppola,et al.  Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. , 2003, Anticancer research.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.